News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
PureTech Health plc - American Depositary Shares
(NQ:
PRTC
)
17.35
+0.34 (+2.00%)
Streaming Delayed Price
Updated: 10:47 AM EDT, May 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about PureTech Health plc - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
Next >
PureTech Announces Annual Results for Year Ended December 31, 2025
April 29, 2026
From
PureTech Health plc
Via
Business Wire
PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange
April 29, 2026
From
PureTech Health plc
Via
Business Wire
PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors
April 27, 2026
From
PureTech Health plc
Via
Business Wire
PureTech (PRTC) Q1 2025 Earnings Transcript
↗
April 21, 2026
PureTech (PRTC) Q1 2025 Earnings Transcript
Via
The Motley Fool
PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine
April 02, 2026
From
PureTech Health plc
Via
Business Wire
PureTech Founded Entity Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo™ in Healthy Volunteers
April 02, 2026
From
PureTech Health plc
Via
Business Wire
PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans
March 25, 2026
From
PureTech Health plc
Via
Business Wire
PureTech to Present at the Leerink Partners Global Healthcare Conference
February 25, 2026
From
PureTech Health plc
Via
Business Wire
PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
February 19, 2026
From
PureTech Health plc
Via
Business Wire
PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference
January 06, 2026
From
PureTech Health plc
Via
Business Wire
PureTech Appoints Robert Lyne as Chief Executive Officer
December 18, 2025
From
PureTech Health plc
Via
Business Wire
PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
December 08, 2025
From
PureTech Health plc
Via
Business Wire
PureTech’s Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
December 05, 2025
From
PureTech Health plc
Via
Business Wire
PureTech’s Founded Entity Gallop Oncology to Present New Data from Ongoing Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the American Society of Hematology (ASH) Annual Meeting
November 03, 2025
From
PureTech Health plc
Via
Business Wire
PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group
October 22, 2025
From
PureTech Health plc
Via
Business Wire
PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF
September 29, 2025
From
PureTech Health plc
Via
Business Wire
CoreWeave, Barrick Mining, FedEx And Other Big Stocks Moving Higher On Friday
↗
September 19, 2025
Via
Benzinga
PureTech Founded Entity Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgo™ (SPT-320) in Healthy Volunteers
September 11, 2025
From
PureTech Health plc
Via
Business Wire
PureTech (PRTC) Q2 2025 Earnings Call Transcript
↗
September 02, 2025
Via
The Motley Fool
Topics
Earnings
PureTech Health Cash Runway Extended
↗
September 02, 2025
Via
The Motley Fool
Earnings Scheduled For August 28, 2025
↗
August 28, 2025
Via
Benzinga
PureTech Health plc – Half-Year Report
August 28, 2025
From
PureTech Health plc
Via
Business Wire
PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF
August 21, 2025
From
PureTech Health plc
Via
Business Wire
PureTech Health: Notice of Half-Yearly Results
August 18, 2025
From
PureTech Health plc
Via
Business Wire
PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint
August 13, 2025
From
PureTech Health plc
Via
Business Wire
PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases
August 12, 2025
From
PureTech Health plc
Via
Business Wire
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo™ (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress
July 17, 2025
From
PureTech Health plc
Via
Business Wire
PureTech Announces Leadership Transition
July 16, 2025
From
PureTech Health plc
Via
Business Wire
PureTech Announces Board Change
July 08, 2025
From
PureTech Health plc
Via
Business Wire
Why This Biotech Stock Just Doubled In A Single Day
↗
June 26, 2025
Vor Biopharma shares surge 43% after licensing deal, $175M raise, and CEO transition.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
